Acorda Therapeutics Stock Performance
| ACOR Stock | USD 0.55 0.00 0.00% |
Acorda Therapeutics holds a performance score of 7 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 2.56, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Acorda Therapeutics will likely underperform. Use Acorda Therapeutics variance, potential upside, as well as the relationship between the Potential Upside and day median price , to analyze future returns on Acorda Therapeutics.
Risk-Adjusted Performance
7 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Acorda Therapeutics are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak basic indicators, Acorda Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 44.4 M |
Acorda |
Acorda Therapeutics Relative Risk vs. Return Landscape
If you would invest 1,655 in Acorda Therapeutics on January 26, 2024 and sell it today you would lose (1,600) from holding Acorda Therapeutics or give up 96.68% of portfolio value over 90 days. Acorda Therapeutics is currently generating 12.3898% in daily expected returns and assumes 136.8426% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Acorda, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Acorda Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Acorda Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Acorda Therapeutics, and traders can use it to determine the average amount a Acorda Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0905
| Best Portfolio | Best Equity | ACOR | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 136.84 actual daily | 96 96% of assets are less volatile |
Expected Return
| 5.04 actual daily | 96 96% of assets have lower returns |
Risk-Adjusted Return
| 0.09 actual daily | 7 93% of assets perform better |
Based on monthly moving average Acorda Therapeutics is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Acorda Therapeutics by adding it to a well-diversified portfolio.
Acorda Therapeutics Fundamentals Growth
Acorda Stock prices reflect investors' perceptions of the future prospects and financial health of Acorda Therapeutics, and Acorda Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Acorda Stock performance.
| Return On Equity | -0.24 | ||||
| Return On Asset | -0.0577 | ||||
| Profit Margin | (2.15) % | ||||
| Operating Margin | 0.04 % | ||||
| Current Valuation | 161.45 M | ||||
| Shares Outstanding | 1.24 M | ||||
| Price To Earning | 0.95 X | ||||
| Price To Book | 0.05 X | ||||
| Price To Sales | 0.01 X | ||||
| Revenue | 117.63 M | ||||
| Gross Profit | 82.43 M | ||||
| EBITDA | 8.4 M | ||||
| Net Income | (252.85 M) | ||||
| Cash And Equivalents | 20.7 M | ||||
| Cash Per Share | 0.85 X | ||||
| Total Debt | 190.9 M | ||||
| Debt To Equity | 2.56 % | ||||
| Current Ratio | 1.71 X | ||||
| Book Value Per Share | (127.17) X | ||||
| Cash Flow From Operations | (13.98 M) | ||||
| Earnings Per Share | (203.57) X | ||||
| Market Capitalization | 821.03 K | ||||
| Total Asset | 117.75 M | ||||
| Retained Earnings | (1.19 B) | ||||
| Working Capital | (152.98 M) | ||||
| Current Asset | 451.32 M | ||||
| Current Liabilities | 90.59 M | ||||
About Acorda Therapeutics Performance
To evaluate Acorda Therapeutics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Acorda Therapeutics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Acorda Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Acorda Therapeutics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Acorda's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 128.06 | 222.89 | |
| Return On Tangible Assets | (2.67) | (2.53) | |
| Return On Capital Employed | 0.21 | 0.20 | |
| Return On Assets | (2.15) | (2.04) | |
| Return On Equity | 1.60 | 1.52 |
Things to note about Acorda Therapeutics performance evaluation
Checking the ongoing alerts about Acorda Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Acorda Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Acorda Therapeutics is not yet fully synchronised with the market data | |
| Acorda Therapeutics is way too risky over 90 days horizon | |
| Acorda Therapeutics has some characteristics of a very speculative penny stock | |
| Acorda Therapeutics appears to be risky and price may revert if volatility continues | |
| Acorda Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 117.63 M. Net Loss for the year was (252.85 M) with profit before overhead, payroll, taxes, and interest of 82.43 M. | |
| Acorda Therapeutics currently holds about 20.7 M in cash with (13.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.85, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from seekingalpha.com: Molecular Templates, Acorda Therapeutics, MyMD Pharmaceuticals among healthcare movers |
- Analyzing Acorda Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Acorda Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Acorda Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Acorda Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Acorda Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Acorda Therapeutics' stock. These opinions can provide insight into Acorda Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Complementary Tools for Acorda Stock analysis
When running Acorda Therapeutics' price analysis, check to measure Acorda Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acorda Therapeutics is operating at the current time. Most of Acorda Therapeutics' value examination focuses on studying past and present price action to predict the probability of Acorda Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acorda Therapeutics' price. Additionally, you may evaluate how the addition of Acorda Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |
Is Acorda Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Acorda Therapeutics. If investors know Acorda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Acorda Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 5.873 | Earnings Share (203.57) | Revenue Per Share 94.713 | Quarterly Revenue Growth 0.207 | Return On Assets (0.06) |
The market value of Acorda Therapeutics is measured differently than its book value, which is the value of Acorda that is recorded on the company's balance sheet. Investors also form their own opinion of Acorda Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Acorda Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Acorda Therapeutics' market value can be influenced by many factors that don't directly affect Acorda Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Acorda Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Acorda Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Acorda Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.